Gilead Sciences Inc. (NASDAQ:GILD) registered a 0.06% increase, still its new closing price is 2.12% up from the company’s 1 year high of 101.25.It posted 0.35% gains in previous 5 sessions and is now the subject of 12 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 8 buy or better ratings. The 29 stock analysts following this company have an average price target at $93.58, with individual PT in the $74.29-$118.00 range. The shares moved at $71.26, implying that brokerage firms see shares losing about -16.70% in twelve months time.

Gilead Sciences Inc. (GILD) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a -0.49% fall year to date. A Executive Chairman at Gilead Sciences Inc. (GILD) offloaded shares in a transaction closed on Tuesday January 03, 2017. MARTIN JOHN C sold 73,337 shares in the company at $73.59 each and collected $5,396,001 in proceeds. MARTIN JOHN C now owns 3,131,096 shares in the company after this transaction. A Executive Chairman in the company, MARTIN JOHN C, disclosed a transaction on Thursday December 01, 2016 that ended up generating $7,333,000 from the sale of 100,000 shares at $73.33 per share.

Gilead Sciences Inc. (NASDAQ:GILD) Upcoming Results on Tap

Gilead Sciences Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $2.61 in that period. Sales during the quarter are predicted to arrive at $7.11 billion.

Earnings surprise history: Last quarter, the company posted approximately $7.5 billion in revenue and EPS of $2.75. The mean forecast was for $7.45 billion and $2.86 a share, respectively. One quarter earlier, revenue for the stock was at $7.78 billion, with earnings at $3.08/share.

Gilead Sciences Inc. (GILD) Brokerage Update

Gilead Sciences Inc. (GILD) is in Leerink Partners’s research list so their analyst rating change is noteworthy. These shares were downgraded to Mkt Perform from Outperform by Leerink Partners, according to news reported on Tuesday September 27, 2016.Another important research note was issued by Jefferies on Tuesday September 06, 2016.The firm upgraded GILD to Buy from Hold. Over the last six months and over the last three months, the shares of Gilead Sciences Inc. (GILD), have changed -11.19% and -4.86%, respectively.